Epizyme (EPZM) Stock Price, News & Analysis

Company Overview

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $1.47 to $1.47
• 50-Day Range: $1.47 to $1.52
• 52-Week Range: $0.41 to $5.80
• Volume: 7,960 shs
• Average Volume: 3.23 million shs
• Market Capitalization: $247.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EPZM Stock Analysis - Frequently Asked Questions

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) posted its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.16. The business's quarterly revenue was up 45.8% compared to the same quarter last year.

What other stocks do shareholders of Epizyme own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Epizyme investors own include Novavax (NVAX), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Applied Materials (AMAT) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 6/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:EPZM
• CIK: 1571498
• Web: www.epizyme.com
• Phone: (617) 229-5872
• Fax: 617-349-0707
• Employees: 250
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$251.12 million
• Net Margins: -391.90%
• Pretax Margin: -391.80%
• Return on Equity: -2,459.33%
• Return on Assets: -69.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.35
• Quick Ratio: 5.19

Sales & Book Value

• Annual Sales: $37.43 million
• Price / Sales: 6.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.54) per share
• Price / Book: -2.72

Miscellaneous

• Outstanding Shares: 168,329,000
• Free Float: 128,968,000
• Market Cap: $247.44 million
• Optionable: Optionable
• Beta: -0.41